Supernus Pharmaceuticals | SUPN - Operating Expenses


Supernus Pharmaceuticals reported $197.75M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
ANI Pharmaceuticals USD 217.93M 287.88M Dec/2025
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Canopy Growth CAD 87.2M 6.22M Dec/2025
Cara Therapeutics USD 5.94M 983K Sep/2025
Corcept Therapeutics USD 197.64M 219K Dec/2025
Eisai JPY 199.9B 16.22B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Pacira USD 193.68M 27.32M Dec/2025
Perrigo USD 1.03B 75.3M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Supernus Pharmaceuticals USD 197.75M 54.54M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Xeris Pharmaceuticals USD 69.03M 1.38M Dec/2025